Fresenius (FRE) Q3 2024 earnings summary

Executive summary

• Achieved 9% organic revenue growth and high single-digit EBIT and EPS growth in Q3 2024, with strong performances from Kabi and Helios segments, and robust cash flow generation.

• Strategic focus on returns, structural productivity, and organic growth has led to sustained improvements in revenue, margins, and cash flow since 2022.

• Upgraded full-year 2024 guidance to 6%-8% organic revenue growth and 8%-11% EBIT growth, reflecting confidence in continued momentum despite headwinds.

• Group-wide cost and productivity savings ahead of plan, with FY 2024 target already achieved.

• Deleveraging continued, leverage ratio improved to 3.24x, supported by strong cash flow.

Financial highlights

• Q3 2024 revenue: €5.3 billion (+9% organic); EBIT: €552 million (+9%); EPS up 12% year-over-year.

• Operating cash flow reached €763 million in Q3; free cash flow for the last 12 months surged to €2 billion.

• Net income before special items: €388 million (+12%), EPS: €0.69 (+12%).

• Net debt to EBITDA at 3.24x, a 52 bps improvement since year-end.

• ROIC improved to 6.1%.

Outlook and guidance

• Upgraded 2024 guidance: organic revenue growth of 6%-8% and EBIT growth of 8%-11%.

• Kabi: mid- to high-single-digit organic revenue growth, EBIT margin 15–16%.

• Helios: mid-single-digit organic revenue growth, EBIT margin 10–11%.

• Leverage ratio expected at lower end of 3.0-3.5x net debt/EBITDA.

• Guidance factors in headwinds from China, lower biopharma milestone payments in Q4, and loss of energy relief funding.